EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Biologics in hidradenitis suppurativa: Progress and new directions

Alexandra Charrow, Karla Santiago-Soltero, Martina Porter

Journal of the American Academy of Dermatology · 2024-12 · 91 (6) · S27-S30

DOI: 10.1016/j.jaad.2024.09.027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2024-12. Verfasst von Alexandra Charrow und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham & Women's Hospital, Boston, Massachusetts. Electronic address: acha…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Adalimumab, Biological Products, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are currently 2 Food and Drug Administration-approved treatments for hidradenitis suppurativa, and both are biologic medication -- Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha and Secukinumab, an interleukin-17A inhibitor. While both medications have demonstrated modest benefit in patients with hidradenitis suppurativa, patients may lose response over time and neither treatment works in all patients. This review outlines the use of these 2 Food and Drug Administration-approved treatments, the best timing of biologic therapy initiation, the evolving pipeline of biologic treatments, and how to best utilize therapeutic drug monitoring to increase the longevity of these critical treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaAdalimumabBiological ProductsAntibodies, Monoclonal, HumanizedHumansAntibodies, MonoclonalMaleFemaleSeverity of Illness IndexInterleukin-17Treatment Outcome

Stichwörter der Autor:innen

biologics in HShidradenitis suppurativatreatment review

Substanzen

AdalimumabsecukinumabBiological ProductsAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalInterleukin-17

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham & Women's Hospital, Boston, Massachusetts. Electronic address: acharrow@bwh.harvard.edu.
  • Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham & Women's Hospital, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Zitieren

APA

Charrow, A., Santiago-Soltero, K., & Porter, M. (2024). Biologics in hidradenitis suppurativa: Progress and new directions. Journal of the American Academy of Dermatology, 91(6), S27-S30. https://doi.org/10.1016/j.jaad.2024.09.027

Vancouver

Charrow A, Santiago-Soltero K, Porter M. Biologics in hidradenitis suppurativa: Progress and new directions. Journal of the American Academy of Dermatology. 2024;91(6):S27-S30. doi:10.1016/j.jaad.2024.09.027

BibTeX
@article{Charrow2024,
  author = {Charrow, Alexandra and Santiago-Soltero, Karla and Porter, Martina},
  title = {Biologics in hidradenitis suppurativa: Progress and new directions},
  journal = {Journal of the American Academy of Dermatology},
  year = {2024},
  volume = {91},
  number = {6},
  pages = {S27--S30},
  doi = {10.1016/j.jaad.2024.09.027}
}
Kostenlos starten →